Peptide

PTD-DBM

Also known as

PTD-DBM peptide · protein transduction domain–Dishevelled binding motif · CXXC5-Dvl disrupting peptide · PTD DBM · Wnt hair peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	An experimental hair-growth peptide designed to release a brake on Wnt follicle-growth signaling. Laboratory regrowth explains the interest, not proven human effectiveness.
Forms discussed	Scalp solutions, sprays and microneedling-assisted use dominate. Methyl-vanillate products and separate valproic-acid experiments are different formulations; oral availability is not proof of oral benefit.

Notes

PTD-DBM is an experimental hair-growth peptide discussed mainly as a scalp treatment. People seek less shedding, thicker hair or new growth through a different pathway from finasteride. Accounts include reduced shedding, claimed tiny new hairs and no noticeable benefit; human effectiveness and long-term safety remain uncertain.

A peptide designed to release a growth-signal brake. PTD means protein transduction domain, a cell-entry part; DBM means Dishevelled-binding motif. The intended target is CXXC5, a protein that dampens Wnt signaling involved in follicle growth. Blocking its interaction with Dishevelled encouraged hair growth in laboratory models. That mechanism is the reason for interest, not proof of human regrowth. Lee et al.: Targeting CXXC5 by a competing peptide (Animal context · Accessed 2026-09-30)

Scalp products and combinations dominate the discussion. Posts describe solutions, sprays and microneedling-assisted use. Some products combine PTD-DBM with methyl vanillate; other experiments add valproic acid separately. These are different formulations. The discussions do not establish an interchangeable blend ratio, and oral availability claims do not demonstrate that swallowing it works. Novel peptides discussion: PTD-DBM replies (Community discussion · Accessed 2026-09-30) · I'm starting PTD-DBM and valproic acid today — anyone with experience? (Community discussion · Accessed 2026-09-30) · Oral PTD-DBM available online, worth giving a shot? (Community discussion · Accessed 2026-09-30)

Source context — Lee et al.: Targeting CXXC5 by a competing peptide: Abstract and indexed record inspected, not full paper. Human scalp tissue/cells are not treated-human efficacy evidence. Animal regrowth and wound-neogenesis outcomes do not prove human benefit.

Source context — Novel peptides discussion: PTD-DBM replies: One positive account repeated across replies, not multiple users. Ambiguous units and unconfirmed route; no images proving new follicles. Unsourced claim that higher peptide amounts are harmless is rejected. Ingredient ratio missing.

Source context — I'm starting PTD-DBM and valproic acid today — anyone with experience?: 7.5% is companion VPA, not peptide concentration. Delivery degradation untested; cycle recalled with 'iirc' and no break length. Claimed YouTube successes were not inspected. This author says they are using a different account: linked prior story is not independent corroboration.

Source context — Oral PTD-DBM available online, worth giving a shot?: Availability claim and secondhand efficacy skepticism; no oral dose, absorption measurement or personal outcome. Vendor link not used for sourcing guidance.

What people notice

Less shedding	One serum user associated a month of use with less hair loss, then stopped because of cost. No concentration or hair counts were supplied.
New-hair claims and nonresponse	One commenter described tiny hairs after a couple of months without photos. Other users reported no new growth or no significant change while using additional hair treatments.

Notes

Less hair falling out. A May 2026 serum user associated a month of use with reduced hair loss, then stopped because of cost. The report supplies no concentration or hair counts. Less shedding is a useful personal observation, but it does not establish new follicles or fuller coverage. Any experiences with Ptd-dbm?? (Personal report · Accessed 2026-09-30)

Regrowth beyond maintenance. One peptide-community commenter described tiny new hairs after a couple of months, without photographs. A different user found no new growth from an open bottle while finasteride, daily topical minoxidil and weekly microneedling maintained their hair. Those are separate accounts with different outcomes. Novel peptides discussion: PTD-DBM replies (Community discussion · Accessed 2026-09-30) · PTD-DBM from TailorMade (Personal report · Accessed 2026-09-30)

Waiting longer did not always bring results. On HairLossTalk, rocket_hare reported no significant change at 5–6 weeks; Photon reported none after roughly four months with valproic acid. Other hair treatments or uncertain products complicated both accounts. Trying To Explore The Ptd/dbm Route And Failing (Community discussion · Accessed 2026-09-30)

Source context — Any experiences with Ptd-dbm??: Anonymous uncontrolled serum account; no concentration, application volume, photos, counts or off-treatment follow-up. Replies repeating study claims are not human results.

Source context — PTD-DBM from TailorMade: No stated peptide amount or bottle duration; concurrent treatment and subjective outcome. The advertising question itself is not evidence of benefit.

Source context — Trying To Explore The Ptd/dbm Route And Failing: Unverified products, no photos or objective outcome. The 6 mg/0.1 cc statement and quoted 0.6% do not establish a consistent formulation. Injection technique and mixture instructions excluded. Quotes repeating Photon are one account. HairCook's 0.001% clinic report and 0.6% animal comparison are hearsay with incorrect/uncertain species labeling, not calibrated human amounts.

Doses people talk about

Topical frequency	Once or twice daily appears in product/community notes, with microneedling add-ons 1–2 times weekly. Concentration and volume are often missing, so milligrams per application are unknown.
Scalp-injection account	One writer described 6 mg daily with separate topical valproic acid. A later 0.6% description conflicts with the formulation details, leaving the concentration and per-injection amount unverified.
Companion and vial numbers	A 7.5% figure refers to valproic acid, not PTD-DBM. A 5 mg vial question gives container contents, not a reported per-use dose.
Mouse context	10 mM was a mouse topical concentration with laboratory schedules; it is not a human scalp dose.

Notes

Topical sprays: once or twice daily; amount often missing. The retained product/community record describes clean, dry scalp application, often in the evening. It also records microneedling add-ons 1–2 times weekly. These frequencies do not reveal milligrams per application. The month-long serum account gives neither concentration nor applied volume. Any experiences with Ptd-dbm?? (Personal report · Accessed 2026-09-30)

One scalp-injection account: 6 mg daily. John Difool also described separate 8.3% topical valproic acid. A later quotation calls the peptide 0.6%. These inconsistent descriptions do not establish a verified concentration, per-injection amount or successful outcome. Trying To Explore The Ptd/dbm Route And Failing (Community discussion · Accessed 2026-09-30)

7.5% valproic acid is a separate claim. A Reddit poster mentioned this solution concentration while asking how many milligrams of PTD-DBM others used. It describes the companion ingredient, not a peptide dose or a tested blend ratio. A newer injection question mentions a 5 mg vial; vial contents likewise are not a per-use amount. I'm starting PTD-DBM and valproic acid today — anyone with experience? (Community discussion · Accessed 2026-09-30) · PTD-DBM peptide (Community discussion · Accessed 2026-09-30)

10 mM was a mouse topical concentration. The 2023 paper applied it every other day from day 8 to day 12 or 20 after depilation; separate wound experiments used daily application from day 7 to day 21 or 25. These are mouse schedules, not human doses. The paper also studies KY19382, a distinct small molecule, not another PTD-DBM formulation. Ryu et al.: CXXC5 mediates DHT-induced androgenetic alopecia via PGD2 (Animal context · Accessed 2026-09-30)

Source context — PTD-DBM peptide: Question, not a use log. The 2 mg/12-week reply concerns copper peptides, not PTD-DBM, and must not be imported as its regimen.

Source context — Ryu et al.: CXXC5 mediates DHT-induced androgenetic alopecia via PGD2: Abstract/figure legends inspected, not full article. Mouse concentration is not a human amount; no skin-residence or human half-life measurement. Investigator disclosed a company licensing interest.

Half-life, onset & duration

Visible onset	One user reported less shedding in a month, another tiny hairs after a couple of months. Others saw no significant change at 5–6 weeks or roughly four months.
Effect duration	Single-application duration and lasting benefit after stopping are unanswered. Local-signal and restart claims do not document a relapse clock.
Half-life	No dependable human blood or skin half-life is established. Evening application and daily bottle instructions do not measure how long it remains.

Notes

One month for less shedding; a couple of months for claimed tiny hairs. These are the serum user's observation window and the peptide commenter's report, respectively. The latter suggested up to six months for hairs to develop, without documenting that outcome. Neither gives a predictable onset, and PTD-DBM cannot inherit minoxidil's timeline from comparisons alone. Any experiences with Ptd-dbm?? (Personal report · Accessed 2026-09-30) · Novel peptides discussion: PTD-DBM replies (Community discussion · Accessed 2026-09-30)

Lasting benefit after stopping is unanswered. A peptide-thread reply asks whether claimed new follicles would disappear when use ends; it supplies no follow-up result. The serum user's month of less shedding also ends without an after-stopping account. Weeks or months spent applying a product do not measure the effect of one application. Novel peptides discussion: PTD-DBM replies (Community discussion · Accessed 2026-09-30) · Any experiences with Ptd-dbm?? (Personal report · Accessed 2026-09-30)

Local-signal assumptions are still assumptions. The retained discussion assumes any Wnt push ends after stopping and describes restarting after a missed week. It does not document a relapse clock, a withdrawal syndrome or a proven maintenance requirement.

No dependable human estimate in these accounts. Neither the practical reports nor the retained timing notes provide a measured time for half the peptide to disappear from blood or skin. Evening application and daily bottle instructions are habits, not evidence that PTD-DBM lasts overnight or has a particular half-life. I'm starting PTD-DBM and valproic acid today — anyone with experience? (Community discussion · Accessed 2026-09-30)

Cycles people discuss

Testing and ongoing use	8–16-week photo checkpoints and continued application both appear. A month or two followed by an unspecified break was one recalled suggestion, not a standard course.
Unplanned stopping	Cost ended one month-long serum trial; another user ran out after three weeks with valproic acid. These interruptions do not establish a biological reset.

Notes

8–16-week trials and ongoing use both appear. The retained community record describes photo checkpoints after 8–16 weeks and continued application by people who believe it helps. These are testing habits, not an established on/off cycle. Cost ended the serum trial; another user canceled a subscription after noticing no new growth. Any experiences with Ptd-dbm?? (Personal report · Accessed 2026-09-30) · PTD-DBM from TailorMade (Personal report · Accessed 2026-09-30)

A month or two, then a break, is one recalled suggestion. A Reddit commenter proposed this from memory without a break length or supporting outcome. It competes with continuous-use talk rather than defining a standard course. I'm starting PTD-DBM and valproic acid today — anyone with experience? (Community discussion · Accessed 2026-09-30)

Three-week interruption. Georgie ran out after three weeks of PTD-DBM with valproic acid. This was supply-limited, not a planned cycle. Has Anyone Had Results With Lithium Chloride Or Vpa? (Community discussion · Accessed 2026-09-30)

Source context — PTD-DBM from TailorMade: No stated peptide amount or bottle duration; concurrent treatment and subjective outcome. The advertising question itself is not evidence of benefit.

Source context — Has Anyone Had Results With Lithium Chloride Or Vpa?: Brief personal exposure and secondhand group impression; no denominator, measured dose or controlled outcome. VPA-only and lithium-only failures are not PTD-DBM experiences.

Stacks

Hair-treatment combinations	Minoxidil, finasteride/dutasteride, microneedling and PRP appear in saved combinations, with GHK-Cu also discussed.
Multi-ingredient experiments	One long stack included valproic acid, topical dutasteride, latanoprost, thymosin beta-4, GHK-Cu and zinc thymulin. The writer recalled benefit from dutasteride but was unsure about the peptides.

Notes

Minoxidil: Concurrent use prevents improved hair density from being assigned to PTD-DBM alone. [community]

Finasteride or dutasteride: These appear in combination accounts; a different intended pathway does not prove added benefit. [community]

+ Microneedling / PRP: Clinic combo posts. [community]

+ GHK-Cu: Copper-peptide scalp stacks. [community]

Stacks blur the answer. One retrospective user recalled about a year of PTD-DBM with valproic acid among topical dutasteride, latanoprost, thymosin beta-4, GHK-Cu and zinc thymulin. They remembered benefit from dutasteride but were unsure about the rest. Retained notes also include PRP combinations. More ingredients mean more possible explanations for improvement or irritation. Thoughts on a previous stack m (Personal report · Accessed 2026-09-30)

Source context — PTD-DBM from TailorMade: No stated peptide amount or bottle duration; concurrent treatment and subjective outcome. The advertising question itself is not evidence of benefit.

Source context — Thoughts on a previous stack m: Retrospective memory and extensive combinations; price is for whole stack. No exact PTD-DBM amount or measurable outcome. Relative date not turned into invented publication date.

Watch for

Scalp irritation	Alcohol-vehicle sting and dermatitis are noted, especially on needled skin. Irritation does not demonstrate hair growth.
Product and growth-pathway uncertainty	Human long-term safety, product identity and concentration remain uncertain. Topical use does not prove zero systemic absorption; theoretical Wnt concerns do not establish that PTD-DBM causes cancer.
Quiet short reports	Two writers noticed no side effects, one after only three weeks. These accounts cannot rule out systemic or long-term problems.

Notes

Scalp sting is different from hair growth. The retained notes flag alcohol-vehicle sting and dermatitis, especially on needled skin. Irritation is not evidence that follicles are responding.

Topical does not establish safety or product identity. The retained cautions raise uncertain effects from manipulating a growth pathway and unverified concentration or identity in research products. They do not establish that PTD-DBM causes cancer. Scalp use also does not prove zero absorption, and mouse topical results cannot validate oral or injected products.

No noticed side effects in two accounts. JelloSquirrel and Georgie said they noticed no side effects. Georgie's peptide use lasted three weeks; neither account rules out systemic effects or long-term problems. Novel peptides discussion: PTD-DBM replies (Community discussion · Accessed 2026-09-30) · Has Anyone Had Results With Lithium Chloride Or Vpa? (Community discussion · Accessed 2026-09-30)

Full notes

What the Wnt hair peptide actually is

A peptide designed to release a growth-signal brake. PTD means protein transduction domain, a cell-entry part; DBM means Dishevelled-binding motif. The intended target is CXXC5, a protein that dampens Wnt signaling involved in follicle growth. Blocking its interaction with Dishevelled encouraged hair growth in laboratory models. That mechanism is the reason for interest, not proof of human regrowth. Animal context
Scalp products and combinations dominate the discussion. Posts describe solutions, sprays and microneedling-assisted use. Some products combine PTD-DBM with methyl vanillate; other experiments add valproic acid separately. These are different formulations. The discussions do not establish an interchangeable blend ratio, and oral availability claims do not demonstrate that swallowing it works. Reddit r/Peptides Reddit r/tressless Reddit r/tressless Community

What people hope to change

Less hair falling out. A May 2026 serum user associated a month of use with reduced hair loss, then stopped because of cost. The report supplies no concentration or hair counts. Less shedding is a useful personal observation, but it does not establish new follicles or fuller coverage. Personal report
Regrowth beyond maintenance. One peptide-community commenter described tiny new hairs after a couple of months, without photographs. A different user found no new growth from an open bottle while finasteride, daily topical minoxidil and weekly microneedling maintained their hair. Those are separate accounts with different outcomes. Reddit r/Peptides Personal report

Doses people discuss

Reported quantities and application habits are descriptions, not a regimen.

Topical sprays: once or twice daily; amount often missing. The retained product/community record describes clean, dry scalp application, often in the evening. It also records microneedling add-ons 1–2 times weekly. These frequencies do not reveal milligrams per application. The month-long serum account gives neither concentration nor applied volume. Community Personal report
One scalp-injection account: 6 mg daily. John Difool also described separate 8.3% topical valproic acid. A later quotation calls the peptide 0.6%. These inconsistent descriptions do not establish a verified concentration, per-injection amount or successful outcome. HairLossTalk
7.5% valproic acid is a separate claim. A Reddit poster mentioned this solution concentration while asking how many milligrams of PTD-DBM others used. It describes the companion ingredient, not a peptide dose or a tested blend ratio. A newer injection question mentions a 5 mg vial; vial contents likewise are not a per-use amount. Reddit r/tressless Reddit r/HairlossResearch

Half-life

No dependable human estimate in these accounts. Neither the practical reports nor the retained timing notes provide a measured time for half the peptide to disappear from blood or skin. Evening application and daily bottle instructions are habits, not evidence that PTD-DBM lasts overnight or has a particular half-life. Community Reddit r/tressless

Onset: when a change is noticed

One month for less shedding; a couple of months for claimed tiny hairs. These are the serum user's observation window and the peptide commenter's report, respectively. The latter suggested up to six months for hairs to develop, without documenting that outcome. Neither gives a predictable onset, and PTD-DBM cannot inherit minoxidil's timeline from comparisons alone. Personal report Reddit r/Peptides
Waiting longer did not always bring results. On HairLossTalk, rocket_hare reported no significant change at 5–6 weeks; Photon reported none after roughly four months with valproic acid. Other hair treatments or uncertain products complicated both accounts. HairLossTalk

Duration: what persists after use

Lasting benefit after stopping is unanswered. A peptide-thread reply asks whether claimed new follicles would disappear when use ends; it supplies no follow-up result. The serum user's month of less shedding also ends without an after-stopping account. Weeks or months spent applying a product do not measure the effect of one application. Reddit r/Peptides Personal report
Local-signal assumptions are still assumptions. The retained discussion assumes any Wnt push ends after stopping and describes restarting after a missed week. It does not document a relapse clock, a withdrawal syndrome or a proven maintenance requirement. Community

Cycles and reasons for stopping

8–16-week trials and ongoing use both appear. The retained community record describes photo checkpoints after 8–16 weeks and continued application by people who believe it helps. These are testing habits, not an established on/off cycle. Cost ended the serum trial; another user canceled a subscription after noticing no new growth. Community Personal report Personal report
A month or two, then a break, is one recalled suggestion. A Reddit commenter proposed this from memory without a break length or supporting outcome. It competes with continuous-use talk rather than defining a standard course. Reddit r/tressless
Three-week interruption. Georgie ran out after three weeks of PTD-DBM with valproic acid. This was supply-limited, not a planned cycle. HairLossTalk

What to watch for

Scalp sting is different from hair growth. The retained notes flag alcohol-vehicle sting and dermatitis, especially on needled skin. Irritation is not evidence that follicles are responding. Community
No noticed side effects in two accounts. JelloSquirrel and Georgie said they noticed no side effects. Georgie's peptide use lasted three weeks; neither account rules out systemic effects or long-term problems. Reddit r/Peptides HairLossTalk
Topical does not establish safety or product identity. The retained cautions raise uncertain effects from manipulating a growth pathway and unverified concentration or identity in research products. They do not establish that PTD-DBM causes cancer. Scalp use also does not prove zero absorption, and mouse topical results cannot validate oral or injected products. Community

What makes the experiences hard to compare

Stacks blur the answer. One retrospective user recalled about a year of PTD-DBM with valproic acid among topical dutasteride, latanoprost, thymosin beta-4, GHK-Cu and zinc thymulin. They remembered benefit from dutasteride but were unsure about the rest. Retained notes also include PRP combinations. More ingredients mean more possible explanations for improvement or irritation. Personal report Community
Price and delivery doubts matter, but do not explain every failure. A Reddit nonresponder blamed warm delivery and suspected degradation without testing the product. The retrospective stack user recalled spending about $1,000 monthly across the entire stack, not on PTD-DBM alone. These accounts show why people abandon experiments; they do not prove that refrigeration or a higher amount would make an unsuccessful product work. Reddit r/tressless Personal report
Interest in an oral version is not an oral result. The oral thread's author ultimately said they had not tried it. Elsewhere, unclear application quantities and unanswered route questions undermine a positive report. Claims about tiny new follicles are visual impressions, not measurements confirming that entirely new follicles formed. Reddit r/tressless Reddit r/Peptides

Where the mouse numbers belong

10 mM was a mouse topical concentration. The 2023 paper applied it every other day from day 8 to day 12 or 20 after depilation; separate wound experiments used daily application from day 7 to day 21 or 25. These are mouse schedules, not human doses. The paper also studies KY19382, a distinct small molecule, not another PTD-DBM formulation. Animal context